Simultaneous quantification of a non-nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positive ion electrospray tandem mass spectrometry

Biomedical Chromatography

Volumn 23, Issue 4, 2009, Pages 371-381

  Nirogi, Ramakrishna ^a   Bhyrapuneni, Gopinadh ^a,b   Kandikere, Vishwottam ^a   Mudigonda, Koteshwara ^a   Komarneni, Prashanth ^a   Aleti, Raghupathi ^a   Mukkanti, K ^b  

^a SUVEN LIFE SCIENCES LTD   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

Efavirenz; Emtricitabine; Liquid chromatography tandem mass spectrometry; Pharmacokinetic study; Tenofovir

Indexed keywords

BIOMOLECULES; MASS SPECTROMETRY; PHARMACOKINETICS; PHASE SEPARATION; PLASMA (HUMAN); POSITIVE IONS;

ANALYTES; EFAVIRENZ; EMTRICITABINE; HUMAN PLASMAS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; PHARMACOKINETIC STUDIES; POSITIVE ION ELECTROSPRAY TANDEM MASS SPECTROMETRIES; REVERSE-TRANSCRIPTASE; TENOFOVIR;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EFAVIRENZ; EMTRICITABINE; PROPRANOLOL; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; TENOFOVIR;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROSPRAY MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; NONHUMAN; RAT; RODENT; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; TIME; VALIDATION PROCESS;

RODENTIA;

EID: 65249123231     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1125     Document Type: Article

References (26)

1. Aymard G, Legrand M, Trichereau N and Diquet B. Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high performance liquid chromatography. Journal of Chromatography B 2000; 744: 227.
2. Chesney M. Adherence to HAART regimens. AIDS Patient care STDS 2003; 17: 169.
3. Egge-Jacobsen W, Unger M, Niemann CU, Baluom M, Hirai S, Benet LZ and Christians U. Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors. Therapeutic Drug Monitoring 2004; 26: 546.
4. Frampton JE and Croom KF. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. Drugs 2006; 66: 1501.
5. Friedl AC, Ledergerber B, Flepp M, Hirschel B, Telenti A, Furrer H, Bucher HC, Bernasconi E and Weber R. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS 2001; 15: 1793.
6. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ and Cheng AK. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New England Journal of Medicine 2006; 354: 251.
7. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA and Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 1997; 337: 734.
8. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP and Richman DD. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. The Journal of the American Medical Association 2000; 283: 229.
9. Hirabayashi Y, Tsuchiya K, Kimura S and Oka S. Simultaneous determination of six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir), the active metabolite of nelfinavir (M8) and non-nucleoside reverse transcriptase inhibitor (efavirenz) in human plasma by high-performance liquid chromatography. Biomedical Chromatography 2006; 20: 28.
10. Keil K, Frerichs VA, DiFrancesco R and Morse G. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. Therapeutic Drug Monitoring 2003; 25: 340.
11. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H, Francioli P and Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353: 863.
12. Mathias AA, Hinkle J, Menning M, Hui J, Kaul S and Kearney BP. Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. Journal of Acquired Immune Deficiency Syndrome 2007; 46: 167.
13. Matuszewski BK, Constanzer ML and Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 75: 3019.
14. Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin A, Goebel FD, Phillips AN, Clotet B and Lundgren JD. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003; 17: 1741.
15. Notari S, Bocedi A, Ippolito G, Narciso P, Pucillo LP, Tossini G, Donnorso RP, Gasparrini F and Ascenzi P. Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. Journal of Chromatography B 2006; 831: 258.
16. Poirier JM, Robidou P and Jaillon P. Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography. Therapeutic Drug Monitoring 2002; 24: 302.
17. Poirier JM, Robidou P and Jaillon P. Simple and simultaneous determination of the HIV-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography. Therapeutic Drug Monitoring 2005; 27: 186.
18. Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos NC, Becker SL, Wulfsohn M, Miller MD, Toole JJ, Coakley DF and Cheng A. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Annals of Internal Medicine 2003; 139: 313.
19. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ and Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. New England Journal of Medicine 1999; 341: 1865.
20. Staswewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H and Spreen W. Abacavir-lamivudinezidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. The Journal of the American Medical Association 2001; 285: 1155.
21. Titier K, Lagrange F, Pehourcq F, Edno-Mcheik L, Moore N and Molimard M. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma. Therapeutic Drug Monitoring 2002; 24: 417.
22. Tribut O, Arieux C, Michelet C, Chapplain JM, Allain H and Bentue-Ferrer D. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography. Therapeutic Drug Monitoring 2002; 24: 554.
23. Tribut O, Verdier MC, Ariveux C, Allain H, Michelet C and Bentue-Ferrer D. Simultaneous quantitative assay of atazanavir and 6 other HIV protease inhibitors by isocratic reversed-phase liquid chromatography in human plasma. Therapeutic Drug Monitoring 2005; 27: 265.
24. Usami Y, Oki T, Nakai M, Sagisaka M and Kaneda T. A simple HPLC method for simultaneous determination of lopinavir, ritonavir and efavirenz. Chemical Pharmaceutical Bulletin 2003; 51: 715.
25. US Department of Health and Human Services. The Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adole-scents. May 9, 2008 [online]. Available from URL: http://AIDSinfo.nih.gov [Accessed 8 June 2008].
26. Villani P, Feroggio M, Gianelli L, Bartoli A, Montagna M, Maserati R and Regazzi MB. Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography-mass spectrometry assay. Therapeutic Drug Monitoring 2001; 23: 380.